NCT06823245View on ClinicalTrials.gov

Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

HS-10241

HS-10241 administered orally once at D1

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY